Segment Reporting (Tables)

9 Months Ended

Sep. 30, 2026

Schedule of Disaggregated Research and Development Expenses and Segment Net Loss

In addition to the significant expense categories included on the Company's consolidated statements of operations, refer below for disaggregated amounts that comprise research and development expenses and the segment net loss (in thousands):


	For the three months ended September 30,						For the nine months ended September 30,
	2026			2025			2026			2025
Operating expenses:
Research and development operating expenses excluding non-cash stock-based compensation:
Primary program research and development expenses (a)	$	18,574		$	15,414		$	50,481		$	46,862
Other research and development expenses:
Payroll and benefits		3,639			3,514			10,257			9,611
Occupancy and other overhead and operating costs		478			557			1,679			1,631
Total other research and development expenses		4,117			4,071			11,936			11,242
Research and development operating expenses excluding non-cash stock-based compensation:		22,691			19,485			62,417			58,104
General and administrative expense excluding non-cash stock-based compensation		12,968			7,309			34,653			22,860
Other segment income (expense), net (b)		7,330			2,767			23,431			5,637
Segment net loss	$	(42,989	)	$	(29,561	)	$	(120,501	)	$	(86,601	)

Primary program research and development expenses are comprised primarily of costs paid to third parties for clinical trials and product development manufacturing, nonclinical, regulatory, and quality assurance activities, and the portion of related research and development expenses incurred by our collaborators and third-party service providers, including contract research and manufacturing organizations that we are obligated to reimburse.

Other segment income (expense), net includes interest income, interest expense, foreign currency exchange gain or loss, depreciation and amortization, non-cash stock-based compensation, loss on extinguishment of debt (for the nine months ended September 30, 2025), tax credit income, and the change in fair value of the royalty agreement derivative liability.